These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 26448147)
1. Muscle-Derived IL-6 Is Not Regulated by IL-1 during Exercise. A Double Blind, Placebo-Controlled, Randomized Crossover Study. Nordmann TM; Seelig E; Timper K; Cordes M; Coslovsky M; Hanssen H; Schmidt-Trucksäss A; Donath MY PLoS One; 2015; 10(10):e0139662. PubMed ID: 26448147 [TBL] [Abstract][Full Text] [Related]
2. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. Larsen CM; Faulenbach M; Vaag A; Vølund A; Ehses JA; Seifert B; Mandrup-Poulsen T; Donath MY N Engl J Med; 2007 Apr; 356(15):1517-26. PubMed ID: 17429083 [TBL] [Abstract][Full Text] [Related]
3. The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance. van Poppel PC; van Asseldonk EJ; Holst JJ; Vilsbøll T; Netea MG; Tack CJ Diabetes Obes Metab; 2014 Dec; 16(12):1269-73. PubMed ID: 25039318 [TBL] [Abstract][Full Text] [Related]
4. IL-1 receptor antagonism and muscle gene expression in patients with type 2 diabetes. Berchtold LA; Larsen CM; Vaag A; Faulenbach M; Workman CT; Kruhøffer M; Donath M; Mandrup-Poulsen T Eur Cytokine Netw; 2009 Jun; 20(2):81-7. PubMed ID: 19541594 [TBL] [Abstract][Full Text] [Related]
5. Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. van Asseldonk EJ; Stienstra R; Koenen TB; Joosten LA; Netea MG; Tack CJ J Clin Endocrinol Metab; 2011 Jul; 96(7):2119-26. PubMed ID: 21508140 [TBL] [Abstract][Full Text] [Related]
6. Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. Grundtman C; Salomonsson S; Dorph C; Bruton J; Andersson U; Lundberg IE Arthritis Rheum; 2007 Feb; 56(2):674-87. PubMed ID: 17265504 [TBL] [Abstract][Full Text] [Related]
7. Association of soluble apoptotic markers with impaired left ventricular deformation in patients with rheumatoid arthritis. Effects of inhibition of interleukin-1 activity by anakinra. Ikonomidis I; Tzortzis S; Lekakis J; Paraskevaidis I; Dasou P; Parissis J; Nikolaou M; Markantonis SL; Katsimbri P; Skarantavos G; Andreadou I; Anastasiou-Nana M Thromb Haemost; 2011 Nov; 106(5):959-67. PubMed ID: 21947196 [TBL] [Abstract][Full Text] [Related]
8. Effect of ascorbic acid on microcirculation in patients with Type II diabetes: a randomized placebo-controlled cross-over study. Lu Q; Björkhem I; Wretlind B; Diczfalusy U; Henriksson P; Freyschuss A Clin Sci (Lond); 2005 Jun; 108(6):507-13. PubMed ID: 15675894 [TBL] [Abstract][Full Text] [Related]
9. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Böni-Schnetzler M; Boller S; Debray S; Bouzakri K; Meier DT; Prazak R; Kerr-Conte J; Pattou F; Ehses JA; Schuit FC; Donath MY Endocrinology; 2009 Dec; 150(12):5218-29. PubMed ID: 19819943 [TBL] [Abstract][Full Text] [Related]
10. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Larsen CM; Faulenbach M; Vaag A; Ehses JA; Donath MY; Mandrup-Poulsen T Diabetes Care; 2009 Sep; 32(9):1663-8. PubMed ID: 19542207 [TBL] [Abstract][Full Text] [Related]
11. Serum IL-18 and hsCRP correlate with insulin resistance without effect of calcitriol treatment on type 2 diabetes. Akbarzadeh M; Eftekhari MH; Dabbaghmanesh MH; Hasanzadeh J; Bakhshayeshkaram M Iran J Immunol; 2013 Sep; 10(3):167-76. PubMed ID: 24076594 [TBL] [Abstract][Full Text] [Related]
13. The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus. Donath MY; Mandrup-Poulsen T Nat Clin Pract Endocrinol Metab; 2008 May; 4(5):240-1. PubMed ID: 18317479 [No Abstract] [Full Text] [Related]